Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos

H157

Sigma-Aldrich

HOE 140

≥94% (HPLC), powder or lyophilized powder, B₂ bradykinin receptor antagonist

Faça loginpara ver os preços organizacionais e de contrato
Todas as fotos(1)
Sinônimo(s):
D-Arg-L-Arg-L-Pro-L-Hyp-Gly-L-(2-thienyl)Ala-L-Ser-D-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-L-(2α,3β,7aβ)-octahydro-1H-indole-2-carbonyl-L-Arg, Icatibant acetate
Fórmula empírica (Notação de Hill):
C59H89N19O13S
Número CAS:
138614-30-9
Peso molecular:
1304.52
Número MDL:
MFCD00213940
Código UNSPSC:
51111800
ID de substância PubChem:
329815169
NACRES:
NA.32

Nível de qualidade

200

Ensaio

≥94%

temperatura de armazenamento

−20°C

cadeia de caracteres SMILES

N[C@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC(=O)N[C@@H](Cc3cccs3)C(=O)N[C@@H](CO)C(=O)N4Cc5ccccc5C[C@@H]4C(=O)N6[C@H]7CCCC[C@H]7C[C@H]6C(=O)N[C@@H](CCCNC(N)=N)C(O)=O

InChI

1S/C59H89N19O13S/c60-37(14-5-19-67-57(61)62)48(82)72-38(15-6-20-68-58(63)64)52(86)75-22-8-18-43(75)54(88)77-30-35(80)26-44(77)50(84)70-28-47(81)71-40(27-36-13-9-23-92-36)49(83)74-41(31-79)53(87)76-29-34-12-2-1-10-32(34)24-46(76)55(89)78-42-17-4-3-11-33(42)25-45(78)51(85)73-39(56(90)91)16-7-21-69-59(65)66/h1-2,9-10,12-13,23,33,35,37-46,79-80H,3-8,11,14-22,24-31,60H2,(H,70,84)(H,71,81)(H,72,82)(H,73,85)(H,74,83)(H,90,91)(H4,61,62,67)(H4,63,64,68)(H4,65,66,69)/t33-,35+,37+,38-,39-,40-,41-,42-,43-,44-,45-,46+/m0/s1

chave InChI

QURWXBZNHXJZBE-SKXRKSCCSA-N

Informações sobre genes

human ... BDKRB2(624)
mouse ... BDKRB2(12062)
rat ... BDKRB2(25245)

Amino Acid Sequence

Arg-Arg-Pro-Hyp-Gly-Thi-Ser-Tic-Oic-Arg

Ações bioquímicas/fisiológicas

B2 bradykinin receptors are present in the sensory neurons. Activation of B2 receptor by bradykinin is associated with pro-inflammatory, pain producing and cardiovascular responses. HOE-140 is a selective B2 bradykinin receptor antagonist. Presence of HOE-140 suppresses the effects of bradykinin and has been shown to have anti-hyperalgesic response, particularly towards inflammatory pain.

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable

Equipamento de proteção individual

Eyeshields, Gloves, type N95 (US)

Certificados de análise (COA)

Busque Certificados de análise (COA) digitando o Número do Lote do produto. Os números de lote e remessa podem ser encontrados no rótulo de um produto após a palavra “Lot” ou “Batch”.

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Os clientes também visualizaram

Slide 1 of 1

1 of 1

AGN 193109 ≥98% (HPLC)

Sigma-Aldrich

SML2034

AGN 193109

Constanze A Jakwerth et al.
Journal of molecular medicine (Berlin, Germany), 100(4), 613-627 (2022-03-06)
SARS-CoV-2 has evolved to enter the host via the ACE2 receptor which is part of the kinin-kallikrein pathway. This complex pathway is only poorly understood in context of immune regulation but critical to control infection. This study examines SARS-CoV-2-infection and
M G Bock et al.
Current opinion in chemical biology, 4(4), 401-406 (2000-08-26)
The pro-inflammatory, pain producing, and cardiovascular effects of bradykinin B2 receptor activation are well characterized. Bradykinin B1 receptors also produce inflammation and pain. Therefore, antagonists are expected to be anti-inflammatory/analgesic drugs. Other exploitable clinical opportunities may exist. The newly discovered
Xin-Hui Khoo et al.
Cancers, 11(8) (2019-08-17)
Drug resistance remains a severe problem in most chemotherapy regimes. Recently, it has been suggested that cancer cell-derived extracellular vesicles (EVs) could mediate drug resistance. In this study, the role of EVs in mediating the response of oral squamous cell
Carolin Beck et al.
Oral oncology, 48(12), 1208-1219 (2012-07-04)
In this study, we investigated the role of the kallikrein-kinin-system in head and neck squamous cell carcinoma (HNSCC) and its implication on tumour survival, invasion, migration and response to radiotherapy. The expression of BKB2R was studied in a series of
K Wirth et al.
British journal of pharmacology, 102(3), 774-777 (1991-03-01)
1. The potency, duration of action and tolerability of Hoe 140, a novel and highly potent bradykinin (BK) antagonist in vitro, has been tested in different in vivo models and compared with the well-known BK antagonist D-Arg-[Hyp2, Thi5,8, D-Phe7]BK. 2.
Exibir todos os documentos relacionados

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica